<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04851288</url>
  </required_header>
  <id_info>
    <org_study_id>20-0502</org_study_id>
    <secondary_id>R01AG066730</secondary_id>
    <nct_id>NCT04851288</nct_id>
  </id_info>
  <brief_title>Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans</brief_title>
  <official_title>Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Boulder</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of cardiovascular diseases (CVD) occur in men and women ≥60 years of age.&#xD;
      Vascular dysfunction, including endothelial dysfunction, as assessed by reduced&#xD;
      endothelium-dependent dilation (EDD), and stiffening of the large elastic arteries (i.e.,&#xD;
      aortic and carotid artery stiffening), is a major mechanism of increased risk of CVD in older&#xD;
      adults. Excess production of ROS (reactive oxygen species) by mitochondria (mtROS) has&#xD;
      emerged as a central feature of vascular oxidative stress with aging and driver of&#xD;
      age-related vascular dysfunction. As such, identifying novel strategies to decrease mtROS and&#xD;
      improve vascular function, to ultimately reduce the risk of age-related CVD, is an important&#xD;
      biomedical objective.&#xD;
&#xD;
      MitoQ is a mitochondria-targeted antioxidant that accumulates at the inner mitochondrial&#xD;
      membrane where it is optimally positioned to reduce mtROS. Preclinical findings showed that 4&#xD;
      weeks of oral MitoQ supplementation completely restored EDD in old mice, ameliorated&#xD;
      mtROS-associated suppression of EDD, and was associated with reduced arterial mtROS,&#xD;
      oxidative stress, and improved mitochondrial health. MitoQ therapy also reduced aortic&#xD;
      stiffness in old mice. A recent small pilot study of older adults (n=20) found that&#xD;
      supplementation with MitoQ was well-tolerated, improved endothelial function, and reduced&#xD;
      plasma levels of oxidized low-density lipoprotein, a circulating biomarker of oxidative&#xD;
      stress. Consistent with the preclinical findings, preliminary mechanistic assessments in&#xD;
      subsets of subjects from the pilot study suggested that improved endothelial function with&#xD;
      MitoQ was mediated by reduced endothelial cell mtROS production, associated reductions in&#xD;
      tonic mtROS-related suppression of EDD, and improved mitochondrial health, linked in part to&#xD;
      changes in circulating factors in the serum induced by chronic MitoQ supplementation. Lastly,&#xD;
      MitoQ reduced aortic stiffness in older adults who exhibited age-related aortic stiffening at&#xD;
      baseline.&#xD;
&#xD;
      The investigators are conducting a randomized, placebo-controlled, double-blind clinical&#xD;
      trial to establish oral MitoQ (20 mg/day; MitoQ, Ltd.) for 3 months vs. placebo (n=56/group)&#xD;
      for improving endothelial function in older men and women (≥60 years), and determine the&#xD;
      mechanisms by which MitoQ improves endothelial function. The investigators will also assess&#xD;
      the effect of MitoQ on aortic stiffness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in endothelial function at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Brachial artery flow-mediated dilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in suppression of endothelial function by mitochondrial oxidative stress at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Change in brachial artery flow-mediated dilation with acute, supratherapeutic MitoQ (160mg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in aortic stiffness at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Carotid-femoral pulse wave velocity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in serum exposure-induced endothelial cell reactive oxygen species production at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Endothelial cell whole-cell (CellROX) and mitochondria-specific (MitoSOX) reactive oxygen species levels after treatment with serum from subjects</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in endothelial cell markers of oxidative stress and mitochondrial health from baseline at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Endothelial cell protein expression of nitrotyrosine and Fis1</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in carotid artery stiffness at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Carotid artery beta-stiffness index</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in circulating marker of oxidative stress at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Oxidized LDL levels in blood</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>MitoQ, 20 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MitoQ</intervention_name>
    <description>MitoQ is a biochemically modified form of ubiquinol</description>
    <arm_group_label>MitoQ, 20 mg/day</arm_group_label>
    <other_name>Mitoquinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each placebo capsule contains inert excipient and is identical in appearance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 60 years and over&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Willing to accept random assignment to condition&#xD;
&#xD;
          -  Body mass index &lt;40 kg/m2&#xD;
&#xD;
          -  Weight stable in the prior 3 months (&lt;2 kg weight change) and willing to remain weight&#xD;
             stable throughout the study&#xD;
&#xD;
          -  Free from alcohol dependence or abuse,&#xD;
&#xD;
          -  Mini-mental stage examination score ≥21&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled thyroid disease&#xD;
&#xD;
          -  Regular vigorous aerobic (&gt;6 bouts/week, &gt;60 min/bout at a workload &gt;6 METS)&#xD;
&#xD;
          -  Blood donation within 8 weeks prior to enrolling in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas R Seals</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Boulder</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morgan Berryman-Maciel</last_name>
    <phone>303-735-6410</phone>
    <email>MitoQstudy@colorado.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Boulder</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Berryman-Maciel</last_name>
      <phone>303-735-6410</phone>
      <email>MitoQstudy@colorado.edu</email>
    </contact>
    <contact_backup>
      <phone_ext>Seals</phone_ext>
      <email>seals@colorado.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Douglas R Seals, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew J Rossman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado, Boulder</investigator_affiliation>
    <investigator_full_name>Douglas Seals</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

